دوره 1، شماره 1 - ( بهار 1391 )                   جلد 1 شماره 1 صفحات 1-9 | برگشت به فهرست نسخه ها




DOI: 10.18869/acadpub.rmm.1.1.1

XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Valadan R, Rafiei A, Tehrani M, Nejatollahi F. Resistance to HER2-targeted therapy. Res Mol Med (RMM). 2013; 1 (1) :1-9
URL: http://rmm.mazums.ac.ir/article-1-35-fa.html
Resistance to HER2-targeted therapy. Research in Molecular Medicine. 1391; 1 (1) :1-9

URL: http://rmm.mazums.ac.ir/article-1-35-fa.html


چکیده:   (3411 مشاهده)


Production and approval of trastuzumab (Herceptin®) for the treatment of metastatic breast cancer (MBC) was a millstone in antibody-based targeted therapy in the cancer treatment. However, despite the early success in the clinical trials, trastuzumab failed to appreciate the initial attraction due to development of resistance to the drug. The majority of patients who benefit from the drug acquire resistance to it and experience tumor recurrence within 1 year. Several molecular and cellular mechanisms underlying the resistance to trastuzumab have been proposed. In this review, first, we provide a brief history leading to production of trastuzumab. Also we consider the cellular and molecular antitumor effects of trastuzumab and then, we discuss the mechanisms underlying trastuzumab resistance in four levels.

متن کامل [PDF 420 kb]   (1257 دریافت)    
نوع مطالعه: پژوهشي | موضوع مقاله: ايمونولوژي
دریافت: ۱۳۹۱/۱۲/۱۹ | پذیرش: ۱۳۹۲/۵/۲۰ | انتشار: ۱۳۹۲/۵/۲۰

ارسال نظر درباره این مقاله : نام کاربری یا پست الکترونیک شما:
کد امنیتی را در کادر بنویسید

کلیه حقوق این وب سایت متعلق به Research in Molecular Medicine می باشد.

طراحی و برنامه نویسی : یکتاوب افزار شرق

© 2015 All Rights Reserved | Research in Molecular Medicine

Designed & Developed by : Yektaweb